Surrozen Raises $95.1 Million in Final Tranche of Private Placement

• Surrozen closed the second and final tranche of its March 2025 private placement, raising approximately $95.1 million in gross proceeds.
• The closing milestone was triggered by FDA clearance of the SZN-8141 investigational new drug application on October 2, 2026.
• The tranche included approximately 5,700,000 common shares and pre-funded warrants exercisable for approximately 2,500,000 common shares.
• Series E common stock warrants cover approximately 4,100,000 shares at an exercise price of $11.54 per share.
• Expected cash runway extends into 2029, funding the SZN-8141 DUET Phase 1b/2a study and initial SZN-8143 Phase 1b development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Surrozen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610201659PRIMZONEFULLFEED9849890) on October 20, 2026, and is solely responsible for the information contained therein.